首页> 美国卫生研究院文献>Drugs in RD >Stability of Melphalan in 0.9  Sodium Chloride Solutions Prepared in Polyvinyl Chloride Bags for Intravenous Injection
【2h】

Stability of Melphalan in 0.9  Sodium Chloride Solutions Prepared in Polyvinyl Chloride Bags for Intravenous Injection

机译:美法仑在静脉注射聚氯乙烯袋中制备的0.9%氯化钠溶液中的稳定性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Melphalan is an alkylating agent frequently used in an intravenous formulation to treat hematologic malignancies and solid tumors in both adults and children. According to the manufacturer, melphalan is stable in sterile 0.9 % sodium chloride for 90 min at room temperature (RT). Several authors have studied the stability of different concentrations of melphalan; however, most were not adapted to the current manufacturing process applied in pharmaceutical centralized units. This study was conducted to determine the stability of melphalan in 0.9 % sodium chloride solutions at concentrations used for intravenous injection in practice. Melphalan is commonly prepared in diluted solutions ranging from 2 to 4 mg/ml for the treatment of adult patients and at lower concentrations (down to 0.5 mg/ml) for pediatric use. Accordingly, these were the three concentrations chosen for this study. Melphalan concentrations were measured with high-performance thin-layer chromatography (HPTLC). At RT, admixtures prepared at 4 mg/ml were stable for up to 8 h without protection from light; however, at lower concentrations, such as 0.5 and 2 mg/ml, stability did not exceed 2 h. When refrigerated, melphalan was stable for 24 h at 2 mg/ml; however, at 0.5 and 4 mg/ml, the drug was not stable. Melphalan solutions present with limited stability at 0.5, 2, and 4 mg/ml and are not adapted for delayed administration in pharmaceutical centralized units. However, at 4 mg/ml and at RT, a stability of 8 h is very interesting in practice and allows sufficient time for preparation, pharmaceutical control, transport, and administration.
机译:美法仑是一种烷化剂,常用于静脉内制剂中,以治疗成人和儿童的血液系统恶性肿瘤和实体瘤。根据制造商的说法,美法仑在室温(RT)下在无菌的0.9%氯化钠中稳定90分钟。几位作者研究了不同浓度马法兰的稳定性。但是,大多数都不适用于制药集中单元中的当前制造工艺。进行这项研究是为了测定在实践中用于静脉注射的浓度下,美法仑在0.9%氯化钠溶液中的稳定性。美法仑通常在2至4 mg / ml的稀释溶液中制备,用于治疗成年患者,并以较低的浓度(低至0.5 mg / ml)用于儿科。因此,这些是为本研究选择的三个浓度。用高效薄层色谱法(HPTLC)测量Melphalan浓度。在室温下,以4 mg / ml的比例制备的混合物可在长达8小时的时间内保持稳定,且不受光照;但是,在较低的浓度(例如0.5和2 mg / ml)下,稳定性不会超过2小时。冷藏后,美法仑在2 mg / ml下稳定24小时;但是,在0.5和4 mg / ml时,药物不稳定。美法仑溶液在0.5、2和4 mg / ml时具有有限的稳定性,不适用于药物集中式单位的延迟给药。但是,在4 mg / ml和RT下,在实践中8h的稳定性非常有趣,并为制备,药物控制,运输和给药留出了足够的时间。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号